Cysteine-lowering Treatment With Mesna

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

The primary objective of this study is to determine the efficacy of the drug Mesna® (Uromitexan) in healthy participants with overweight or obesity with respect to change in plasma concentrations of total cysteine, following single ascending doses of oral Mesna.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Oslo
• Collaborators: Oslo University Hospital; University of Oxford
• Treatments: Mesna

Criteria

Inclusion Criteria:

• BMI between BMI 27-40 kg/m2

• Age between 18-55 years

• Male

• Healthy as determined by medical evaluation, medical history, physical examination, 12-lead ECG, and laboratory tests

Exclusion Criteria:

• Presence of chronic disease

• Chronic drug use

• Past or intended use of over-the-counter or prescription medication including herbal medications within 14 days prior to dosing

• Veganism

• Strenuous physical activity ≥3 times every week

• Smoking